Selection and characterization of a human neutralizing antibody to human fibroblast growth factor-2

被引:28
作者
Tao, Jun [2 ]
Xiang, Jun-Jian [1 ,2 ]
Li, Dan [2 ]
Deng, Ning [1 ]
Wang, Hong [1 ]
Gong, Yi-Ping [1 ]
机构
[1] Jinan Univ, Lab Antibody Engn, Coll Life Sci & Technol, Guangzhou 510632, Guangdong, Peoples R China
[2] So Med Univ, Sch Basic Med Sci, Dept Immunol, Guangzhou 510515, Guangdong, Peoples R China
关键词
FGF-2; Single-chain Fv; Human antibody; Phage display; Neutralizing; Tumor therapy; ANGIOGENESIS; INHIBITION; RATS;
D O I
10.1016/j.bbrc.2010.03.067
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Compelling evidences suggest that fibroblast growth factor-2 (FGF-2) plays important roles in tumor growth, angiogenesis and metastasis Molecules blocking the FGF-2 signaling have been proposed as anticancer agents. Through screening of a human scFv phage display library, we have isolated several human single-chain Fv fragments (says) that bind to human FGF-2 After expression and purification in bacteria, one scFv, named 1A2, binds to FGF-2 with a high affinity and specificity, and completes with FGF-2 binding to its receptor This 1A2 scFv was then cloned into the plgG1 vector and expressed in 293T cells The purified hIgG1-1A2 antibody showed a high binding affinity of 8 x 10(-9) M to rhFGF-2 In a set of vitro assays, it inhibited various biological activities of FGF-2 such as the proliferation, migration and tube formation of human umbilical vein endothelial cells More importantly, hIgG1-1A2 antibody also efficiently blocked the growth while inducing apoptosis of glioma cells For the first time, we generated a human anti-FGF-2 antibody with proven in vitro anti-tumor activity It may therefore present a new therapeutic candidate for the treatment of cancers that are dependent on FGF-2 signaling for growth and survival (C) 2010 Elsevier Inc All rights reserved
引用
收藏
页码:767 / 773
页数:7
相关论文
共 16 条
[1]   Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene [J].
Barclay, C ;
Li, AW ;
Geldenhuys, L ;
Baguma-Nibasheka, M ;
Porter, GA ;
Veugelers, PJ ;
Murphy, PR ;
Casson, AG .
CLINICAL CANCER RESEARCH, 2005, 11 (21) :7683-7691
[2]   Biological roles of fibroblast growth factor-2 [J].
Bikfalvi, A ;
Klein, S ;
Pintucci, G ;
Rifkin, DB .
ENDOCRINE REVIEWS, 1997, 18 (01) :26-45
[3]  
Coppola G, 1997, ANTICANCER RES, V17, P2033
[4]   Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs [J].
Dunn, IF ;
Heese, O ;
Black, PM .
JOURNAL OF NEURO-ONCOLOGY, 2000, 50 (1-2) :121-137
[5]   Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis [J].
Giavazzi, R ;
Sennino, B ;
Coltrini, D ;
Garofalo, A ;
Dossi, R ;
Ronca, R ;
Tosatti, MPM ;
Presta, M .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (06) :1913-1926
[6]   Selection of large diversities of antiidiotypic antibody fragments by phage display [J].
Goletz, S ;
Christensen, PA ;
Kristensen, P ;
Blohm, D ;
Tomlinson, I ;
Winter, G ;
Karsten, U .
JOURNAL OF MOLECULAR BIOLOGY, 2002, 315 (05) :1087-1097
[7]   Monoclonal antibody strategies to block angiogenesis [J].
Hicklin, DJ ;
Witte, L ;
Zhu, ZP ;
Liao, F ;
Wu, Y ;
Li, YW ;
Bohlen, P .
DRUG DISCOVERY TODAY, 2001, 6 (10) :517-528
[8]  
HON A, 1991, CANCER RES, V51, P6180
[9]   INHIBITION OF ANGIOGENESIS IN RATS BY IL-1 RECEPTOR ANTAGONIST AND SELECTED CYTOKINE ANTIBODIES [J].
HU, DE ;
HORI, Y ;
PRESTA, M ;
GRESHAM, GA ;
FAN, TP .
INFLAMMATION, 1994, 18 (01) :45-58
[10]   17-β-estradiol alters Jurkat lymphocyte cell cycling and induces apoptosis through suppression of Bcl-2 and cyclin A [J].
Jenkins, JK ;
Suwannaroj, S ;
Elbourne, KB ;
Ndebele, K ;
McMurray, RW .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2001, 1 (11) :1897-1911